Weight maintenance with litramine (IQP-G-002AS): A 24-week double-blind, randomized, placebo-controlled study

Journal of Obesity

Volumn 2015, Issue , 2015, Pages

  Grube, Barbara ^a   Chong, Pee Win ^b   Alt, Felix ^c   Uebelhack, Ralf ^c  

^a Practice for General Medicine   (Germany)

^b Zaluvida Corporate SDN Bhd   (Malaysia)

^c Analyze and Realize GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; LITRAMINE; UNCLASSIFIED DRUG; CYCLODEXTRIN; PLANT MEDICINAL PRODUCT;

ADULT; ARTICLE; BODY FAT; BODY FAT MASS; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FAT FREE MASS; FAT MASS; FEMALE; GERMANY; HIP CIRCUMFERENCE; HUMAN; MALE; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SATIETY; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT MAINTENANCE; WEIGHT REDUCTION; CLINICAL TRIAL; DIETARY FIBER; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PHARMACOLOGY; THERAPEUTIC USE;

ADULT; ANTI-OBESITY AGENTS; BODY MASS INDEX; BODY WEIGHT; CYCLODEXTRINS; DIETARY FIBER; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; OBESITY; PLANT PREPARATIONS; WEIGHT LOSS;

EID: 84942280069     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2015/953138     Document Type: Article

References (27)

1. World Health Organisation (WHO), "Obesity and overweight, " Factsheet 311, 2014, http://www.who.int/mediacentre/factsheets/fs311/en/.
2. D. W. HaslamandW. P. T. James, "Obesity, " The Lancet, vol. 366, no. 9492, pp. 1197-1209, 2005.
3. M. Arnold, N. Pandeya, G. Byrnes, et al., "Global burden of cancer attributable to high body-mass index in 2012: a population-based study, " The Lancet Oncology, vol. 16, no. 1, pp. 36-46, 2015.
4. D. Branca, H. Nikogosian, and T. Lobstein, Eds., The Challenge of Obesity in the WHO European Region and the Strategies for Response: Summary, WHO Regional Office for Europe, Copenhagen, Denmark, 2007.
5. R. A. Hammond and R. Levine, "The economic impact of obesity in the United States, " Diabetes, Metabolic Syndrome and Obesity: Targets andTherapy, vol. 3, pp. 285-295, 2010.
6. R. Dobbs, C. Sawers, F. Thompson, et al., Overcoming Obesity: An Initial Economic Analysis, McKinsey Global Institute, 2014.
7. M. D. Jensen, D. H. Ryan, C. M. Apovian, et al., "2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society, " Journal of the American College of Cardiology, vol. 63, no. 25, pp. 2985-3023, 2014.
8. C. M. Kroeger, K. K. Hoddy, andK. A. Varady, "Impactofweight regain on metabolic disease risk: a review of human trials, " Journal of Obesity, vol. 2014, Article ID 614519, 8 pages, 2014.
9. R. Rosenheck, "Fast food consumption and increased caloric intake: a systematic review of a trajectory towards weight gain and obesity risk, " Obesity Reviews, vol. 9, no. 6, pp. 535-547, 2008.
10. H. Schröder, M. Fïto, and M. I. Covas, "Association of fast food consumption with energy intake, diet quality, body mass index and the risk of obesity in a representative Mediterranean population, " British Journal of Nutrition, vol. 98, no. 6, pp. 1274-1280, 2007.
11. C. Tsigos, V. Hainer, A. Basdevant, et al., "Management of obesity in adults: European clinical practice guidelines, " Obesity Facts, vol. 1, no. 2, pp. 106-116, 2008.
12. R. Uebelhack, R. Busch, F. Alt, Z.-M. Beah, and P.-W. Chong, "Effects of cactus fiber on the excretion of dietary fat in healthy subjects: a double blind, randomized, placebocontrolled, crossover clinical investigation, " Current Therapeutic Research-Clinical and Experimental, vol. 76, pp. 39-44, 2014.
13. B. Grube, P.-W. Chong, K.-Z. Lau, and H.-D. Orzechowski, "A natural fiber complex reduces body weight in the overweight and obese: a double-blind, randomized, placebo-controlled study, " Obesity, vol. 21, no. 1, pp. 58-64, 2013.
14. International Association for the Study of Obesity, Overweight and Obesity in the EU, International Association for the Study of Obesity, London, UK, 2008.
15. A. J. Hill, P. J. Rogers, and J. E. Blundell, "Techniques for the experimental measurement of human eating behaviour and food intake: a practical guide, " International Journal of Obesity, vol. 19, no. 6, pp. 361-375, 1995.
16. B. Burton-Freeman, "Dietary fiber and energy regulation, " Journal of Nutrition, vol. 130, no. 2, supplement, pp. 272S-275S, 2000.
17. J. E. Blundell and V. J. Burley, "Satiation, satiety and the action of fibre on food intake, " International Journal of Obesity, vol. 11, supplement 1, pp. 9-25, 1987.
18. K. Johansson, K. Neovius, S. M. DeSantis, S. Rössner, and M. Neovius, "Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis, " Obesity Reviews, vol. 10, no. 5, pp. 564-575, 2009.
19. B. M. Y. Cheung, T. T. Cheung, andN. R. Samaranayake, "Safety of antiobesity drugs, " Therapeutic Advances in Drug Safety, vol. 4, no. 4, pp. 171-181, 2013.
20. C. Torp-Pedersen, I. Caterson, W. Coutinho, et al., "Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis fromthe SCOUT trial, " European Heart Journal, vol. 28, no. 23, pp. 2915-2923, 2007.
21. EMEA, "European Medicines Agency recommends suspension of marketing authorisation for sibutramine," 2010, http://www.ema.europa.eu/ema/index.jsp?curl=pages/news and events/news/2010/01/newsdetail000985.jsp&jsenabled=true.
22. FDA, FDA Drug Safety Communication: FDA Recommends against the Continued Use ofMeridia (Sibutramine), 2010, http://www. fda. gov/Drugs/DrugSafety/ucm228746. htm#Safety Announcement.
23. MHRA, "Europe wide suspension of Marketing Authorisation forAcomplia (rimonabant), " 2009, http://webarchive. nationalarchives. gov. uk/20141205150130/http://www. mhra. gov. uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON028547.
24. S. U. Dombrowski, K. Knittle, A. Avenell, V. Aráujo-Soares, and F. F. Sniehotta, "Long termmaintenance ofweight losswith nonsurgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials, " British Medical Journal, vol. 348, Article IDg2646, 2014.
25. L. Sjöström, A. Rissanen, T. Andersen, et al., "Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients, " The Lancet, vol. 352, no. 9123, pp. 167-172, 1998.
26. EFSA Panel on Dietetic Products-Nutrition and Allergies (NDA), "Guidance on the scientific requirement for health claims related to appetite ratings, weight management, and blood glucose concentration, " EFSA Journal, vol. 10, no. 3, article 2604, 2012.
27. J. S. Torgerson, J. Hauptman, M. N. Boldrin, and L. Sjöström, "XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients, " Diabetes Care, vol. 27, no. 1, pp. 155-161, 2004.